Abstract
The synthesis, biochemical evaluation and molecular modelling of a series of esters based upon testosterone is described. The compounds were tested for human placental aromatase (AR) inhibition in vitro and were found, in general, to be weaker than the standard non-steroidal compound, aminoglutethimide (AG), however, one compound [testosterone 4-nitrobenzoate (15)] was found be some six times more potent than AG. The inhibitory activity of the compounds was rationalised through the use of the novel substrate-haem complex (SHC) approach and suggests that the longer alkyl chain containing compounds bind in a manner that results in steric hindrance between the active site of AR and the carboxylate moiety of the compounds, as such, reduced inhibitory activity is observed. The modelling of compound 15 suggests that an additional hydrogen-bonding group may be present at the active site, which allows this compound to possess greatly increased potency.
Keywords: hydrogen-bonding, carboxylate moiety, testosterone 4-nitrobenzoate, Aromatase
Letters in Drug Design & Discovery
Title: Testosterone Based Esters as Inhibitors of Aromatase (AR) and the use of the Substrate-Haem Complex Approach in the Rationalisation of the Inhibitory Activity of these Compounds
Volume: 1 Issue: 4
Author(s): Shaheen Adat and Sabbir Ahmed
Affiliation:
Keywords: hydrogen-bonding, carboxylate moiety, testosterone 4-nitrobenzoate, Aromatase
Abstract: The synthesis, biochemical evaluation and molecular modelling of a series of esters based upon testosterone is described. The compounds were tested for human placental aromatase (AR) inhibition in vitro and were found, in general, to be weaker than the standard non-steroidal compound, aminoglutethimide (AG), however, one compound [testosterone 4-nitrobenzoate (15)] was found be some six times more potent than AG. The inhibitory activity of the compounds was rationalised through the use of the novel substrate-haem complex (SHC) approach and suggests that the longer alkyl chain containing compounds bind in a manner that results in steric hindrance between the active site of AR and the carboxylate moiety of the compounds, as such, reduced inhibitory activity is observed. The modelling of compound 15 suggests that an additional hydrogen-bonding group may be present at the active site, which allows this compound to possess greatly increased potency.
Export Options
About this article
Cite this article as:
Adat Shaheen and Ahmed Sabbir, Testosterone Based Esters as Inhibitors of Aromatase (AR) and the use of the Substrate-Haem Complex Approach in the Rationalisation of the Inhibitory Activity of these Compounds, Letters in Drug Design & Discovery 2004; 1 (4) . https://dx.doi.org/10.2174/1570180043398579
DOI https://dx.doi.org/10.2174/1570180043398579 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Critical Review on the Unexplored Therapeutic Treasure of Himalayan Ayurvedic Drug Daruharidra (<i>Berberis Aristata</i>)
Current Traditional Medicine Biological Function and Medicinal Research Significance of G-Quadruplex Interactive Proteins
Current Topics in Medicinal Chemistry Methylglyoxal and Advanced Glycation Endproducts: New Therapeutic Horizons?
Recent Patents on Cardiovascular Drug Discovery Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer
Current Cancer Drug Targets Cancer and Phase II Drug-Metabolizing Enzymes
Current Drug Metabolism Pemetrexed: Potential Role in the Adjuvant Chemotherapy of Non-Small Cell Lung Cancer
Current Drug Targets Metastatic Cell Dormancy and Re-activation: An Overview on Series of Molecular Events Critical for Cancer Relapse
Anti-Cancer Agents in Medicinal Chemistry Stereological Quantification of Blood and Lymph Microvessels in Prostate Cancer. Its Relevance for the Anti-angiogenetic Therapy
Current Cancer Therapy Reviews Medicinal Plants as a Source of New Therapeutic Products: Genus Mentha and the Potential Antimicrobial Activity of Extracts and Essential Oils
Current Traditional Medicine mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production
Current Pharmaceutical Design Methotrexate: Should We Start Using it in Clinical Practice?
Current Drug Targets Elasticity Imaging via MRI: Basics, Overcoming the Waveguide Limit, and Clinical Liver Results
Current Medical Imaging CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Adipokines and Cytokines in Non-alcoholic Fatty Liver Disease
Reviews on Recent Clinical Trials Neuroglial Roots of Neurodegenerative Diseases: Therapeutic Potential of Palmitoylethanolamide in Models of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Comparison of Radiohaloanalogues of Meta-Iodobenzylguanidine (MIBG) for a Combined Gene- and Targeted Radiotherapy Approach to Bladder Carcinoma
Medicinal Chemistry Making the Most of Pathological Specimens: Molecular Diagnosis in Formalin-Fixed, Paraffin Embedded Tissue
Current Drug Targets Polysaccharide based Copolymers as Supramolecular Systems in Biomedical Applications
Current Drug Targets Emerging Role of GPR30/GPER1 in Skeletal Metabolism
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)